Site-specific antitumour effects of 2 pyrimidinone compounds in rats. by Eggermont, A. M. et al.
Br. J. Cancer (1986), 54, 337-339
Short Communication
Site-specific antitumour effects of 2 pyrimidinone
compounds in rats
A.M.M. Eggermont', R.L. Marquet2, R.W.F. De Bruin2, W. Weimar3
& J. Jeekell
'Department ofSurgery; 2Laboratoryfor Experimental Surgery and 3Department ofInternal Medicine I,
Dijkzigt University Hospital ofthe Erasmus University Rotterdam, Dr Molewaterplein 40, 3015 GD
Rotterdam, The Netherlands.
Recently a series of 5-halo-6-phenyl pyrimidinones
has been found to induce interferon production in
several animal species (Stringfellow et al., 1980) and
in man (Earhart et al., 1985). These compounds
modulate a variety of immune responses. Most
prominently they enhance the activity of natural
killer (NK) cells (Taggert et al., 1980) and
macrophages (Li et al., 1985). In the experiments
reported here we evaluated the effects of two
pyrimidinones that differ greatly in their ability to
induce interferon (IFN) production. ABPP (2-
amino-5-bromo-6-phenyl-4-pyrimidinone) induces
high serum levels of IFN whereas AIPP (2-amino-5-
iodo-6-phenyl-4-pyrimidinone) does not. Yet, both
agents are equally active in enhancing NK cell
activity (Lotzova et al., 1983). In a previous
communition (Marquet et al., 1983) we have shown
that subcutaneous growth of liposarcoma LS175 in
BN rats is inhibited by IFN. This nonimmunogenic
liposarcoma is of spontaneous origin and has been
found to be NK resistant. In order to investigate
whether the induction of IFN plays a part in the
antitumour effects of ABPP and AIPP we
compared the two agents in the subcutaneous and
in the artificial lung metastasis model, using tumour
LS175. Ten to 12-week old male BN rats were used
in all experiments. The NK cell activity in
peripheral blood lymphocytes (PBL) after the intra-
peritoneal administration of 250mgkg-1 of ABPP
or AIPP was assessed by a standard 3h IICr
release assay as described by Ortaldo et al. (1977).
Control animals received an equal volume of PBS
i.p. The results are shown in Figure 1. A rapidly
established and longlasting +4-fold increase in NK
cell cytotoxicity is seen after the administration of
either agent.
The influence on macrophage activity was
assessed by measuring the ingestion of latex
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Figure 1 Enhancement of NK cell activity in
peripheral blood lymphocytes (PBL) 1, 3 and 9 days
after a single i.p. injection of 250mgkg-1 of AIPP or
ABPP. Control animals received PBS i.p. The
percentage of specific lysis is shown as determined in a
3h 5Cr release assay at an effector-to-target (Yac-1)
ration of40:1.
particles by peritoneal exudate (PE) cells after a
single injection of 250mgkg-1 i.p. of either
pyrimidinone. Phagocytosis was rapidly 3-4 fold
enhanced (within 4h) and remained elevated for 4
days (data not shown). In the s.c. tumour model
2mm cubes of tumour LS175 were implanted s.c. in
the left flank of BN rats. Tumour growth was
assessed on days 4, 7 and 12 by measuring the two
largest perpendicular diameters of the tumour with
calipers. The average diameter was taken as the
measure of tumour size. The inoculation of the
tumour was preceded by i.p. injections of AIPP or
ABPP at a dose of 250mgkg- I on days -3, -2
and -1. The effect of this pretreatment on tumour
growth is illustrated in Figure 2. A significant
inhibition of tumour growth was observed in the
ABPP-treated group (P<0.003) whereas some, but
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Days after tumor implantation
Figure 2 Effect of pretreatment with AIPP or ABPP
on s.c. growth of tumour LS175. AIPP or ABPP were
administered at a dose of 250 mgkg-1 i.p. on days -3,
-2 and -1. The difference between the mean tumour
diameter in the ABPP treated group (0---0) and the
control group (O--- 0) was statistically significant
(P<0.003). No significant inhibition of tumour growth
was observed in the AIPP treated group (the AIPP
treated group (A---A). Each group consisted of 5
animals.
insignificant inhibition was seen after pretreatment
with AIPP.
The same pretreatment schedule was used in the
lung metastasis model. Here a single cell suspension
of 105 tumour cells was injected in the tail vein on
day 0. The rats were sacrificed on day 14 and the
number of lung colonies was counted with the
naked eye after fixation of the lungs in Bouin's
solution. As shown in Table I, a significantly
(P<0.02) lower number of lung colonies was
observed in the rats pretreated with ABPP or AIPP
than in the control group. No difference existed
between the two treated groups.
This inhibitory effect on the'development of lung
metastases is in agreement with the results reported
by Milas et al. (1982) concerning immunogenic as
well as non-immunogenic murine tumours.
The activity of both NK cells and macrophages
at the time of i.v. tumour inoculation was strongly
enhanced as a result of the pretreatment with either
ABPP or AIPP. The activation of these two cells
populations may well explain the results in the lung
metastasis model.
Hanna et al. (1980) have shown that tumour cells
are most sensitive to NK cell cytotoxicity when
they are in a bloodborne or early lodging phase.
The fact that tumour LS175 is NK resistant does
not rule out an important role for activated NK
cells to account for the observed lower number of
lung metastases in the pyrimidone treated groups.
Table I Effect of pretreatment with AIPP or ABPP on
the development of lung metastases after i.v. injection of
i05 LS175 cells
Mean number of
Treatment lung metastases +s.d. Range
PBS 39+ 12 24-56
AIPP 18+ 7 10-23
ABPP 13+ 3 10-16
Effect of administration on days -3, -2 and -1 of
250mgkg- AIPP or ABPPi.p. on the development of
lung metastases, when counted on day 14 after the i.v.
injection of 105 cells of liposarcoma LS175. Control
animals were pretreated with PBS. A significantly lower
(P<0.02) number of metastases were observed after either
AIPP or ABPP pretreatment than in the control animals.
Each group consisted of 5 animals.
(i) In vitro NK resistant tumour cells may be less
resistant in vivo to highly activated NK cells
(Talmadge et al., 1984). (ii) Very high NK cell
activity can be induced in the' lungs of rats by
pyrimidinones (Lotzova et al., 1984). (iii) Activated
NK cells have been shown to produce a variety of
lymphokines like IFN-gamma and IL-2 (Kasahara
et al., 1983).
IFN-gamma especially and a putative more
rapidly working macrophage activating factor
(MAF) secreted by NK cells in the rat and in man
(Gomez et al., 1985) are very potent activators of
alveolar macrophages.
The tumour site specific setting of a high
concentration of (pyrimidinone-activated) macro-
phages further activated by NK-cell-secreted
lymphokines could well explain the observed
inhibition of the development of lung metastases.
The difference in tumour reponse to ABPP and
AIPP in the s.c. tumour model may be related to
the difference in IFN serum levels after the
administration of the two agents involved. When we
observe the growth curve of the tumour in the
ABPP pretreated group it is noted that the tumour
seems to disappear over the first few days.
This is the only antitumour effect observed since
tumour growth follows a parallel course to the
other experimental groups when the tumour
becomes measurable. Apparently tumour
suppression is only short lived and no prolonged
inhibitory effect can be observed.
This could be explained by the fact that high
IFN levels are induced by ABPP for a period of
only 24h (Oku et al., 1984; Lotzova et al., 1984).
Since LS175 has been shown to be IFN sensitive
and IFN can have a direct inhibitory effect on
tumour growth, a high IFN level at the time of s.c.
tumour inoculation may have created the +2 dayANTITUMOUR EFFECTS OF PYRIMIDINONES 339
lag time in tumour growth that is observed in the
animals pretreated with ABPP. Since multiple
injections with ABPP induce a hyporeactive state
and a fall in IFN levels (Oku et al., 1984), as is
observed with many biological response modifiers
(Talmadge et al., 1985), the antitumour effect in the
s.c. model offers little prospect for an effective role
for ABPP in this setting.
The anti-metastasis effect of these pyrimidinones
is the more important observation, especially since
the tumour used was NK resistant.
Interactions between activated NK cells and
activated macrophages, both of which are present in
high numbers in the lungs, may have overcome this
resistance and may have brought about the effective
lysis of the tumour cells by either cell population.
Since the administration of pyrimidinones is
virtually without toxicity or side effects (Earhart et
al., 1985) these agents may hold some promise in
boosting anti-metastasis protective mechanisms in a
peri-operative or otherwise adjuvant setting.
This study was in part supported by a grant from The
Upjohn Company, Kalamazoo, Michigan, USA.
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